Format

Send to

Choose Destination
Med Oncol. 2009;26(2):157-60. doi: 10.1007/s12032-008-9100-0. Epub 2008 Oct 10.

Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report.

Author information

1
Department of Oncology, Quanzhou Hospital of Traditional Chinese Medicine, 215 South Wenling Road, Quanzhou, 362000, People's Republic of China. listar@tom.com

Abstract

Platinum-based chemotherapy regimens are often recommended for patients with unresectable thymic carcinoma. In more than 60 cases, however, the systemic chemotherapy provides little benefit. In this report, we described a case of advanced KIT- and VEGF-positive thymic carcinoma with liver and lung metastasis. The patient, a 46-year-old man, exhibited a resistance to cisplatin-based chemotherapy, but responded to the treatment with sorafenib, a molecular target-based therapy. After 4 months of sorafenib therapy, his lung and liver metastases as well as the mediastinal tumor shrank dramatically. Moreover, the tumors showed stable disease for at least 9 months. To the best of our knowledge, it is the first report about a response of advanced thymic carcinoma to sorafenib. The preliminary study suggested that molecular target-based therapy could be an alternative treatment to those chemotherapy-refractory patients.

PMID:
18846437
DOI:
10.1007/s12032-008-9100-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center